Cost-Consequence Analysis of Single-Dose Dalbavancin Versus Standard of Care for the Treatment of Acute Bacterial Skin and Skin Structure Infections in a Multisite Healthcare System.
Julia GonzalezDiana Carolina AndradeJianli NiuPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021)
Dalbavancin was more costly than SoC for the treatment of ABSSSI, with a higher 30-day readmission rate. Dalbavancin does not offer an economic or efficacy advantage.